Promising Nanotechnology Stocks To Watch Now - July 27th

Key Points

• The article highlights seven promising nanotechnology stocks to watch, including Onto Innovation, OSI Systems, and NVE, as they had the highest dollar trading volume recently.
• Investing in nanotechnology stocks presents potential for transformative innovations but also comes with heightened risks due to technical, regulatory, and market uncertainties.
• Onto Innovation's stock price rose to $99.43 with a market cap of $4.86 billion, while OSI Systems reached $226.08 with a market cap of $3.80 billion during mid-day trading.

Onto Innovation, OSI Systems, NVE, Nano Dimension, Clene, Biodexa Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of publicly traded companies that research, develop or manufacture products using nanotechnology—that is, the manipulation of materials at the atomic or molecular scale. These companies often work on advanced applications in fields such as medicine, electronics, materials science and energy. Investing in nanotechnology stocks can offer exposure to potentially transformative innovations but also carries heightened risk due to technical, regulatory and market uncertainties. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

NYSE:ONTO traded up $1.18 during mid-day trading on Friday, hitting $99.43. The company had a trading volume of 998,598 shares, compared to its average volume of 962,809. Onto Innovation has a fifty-two week low of $85.88 and a fifty-two week high of $228.42. The business's fifty day moving average is $97.83 and its two-hundred day moving average is $130.69. The firm has a market cap of $4.86 billion, a P/E ratio of 22.50, a P/E/G ratio of 0.65 and a beta of 1.45.

Read Our Latest Research Report on ONTO

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ:OSIS traded up $2.05 during mid-day trading on Friday, hitting $226.08. The company had a trading volume of 101,423 shares, compared to its average volume of 176,036. OSI Systems has a fifty-two week low of $129.18 and a fifty-two week high of $241.64. The business's fifty day moving average is $223.08 and its two-hundred day moving average is $205.43. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.38 and a current ratio of 2.11. The firm has a market cap of $3.80 billion, a P/E ratio of 27.50, a P/E/G ratio of 1.91 and a beta of 1.27.

Read Our Latest Research Report on OSIS

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NASDAQ:NVEC traded down $0.30 during mid-day trading on Friday, hitting $63.44. The company had a trading volume of 74,170 shares, compared to its average volume of 84,708. NVE has a fifty-two week low of $51.50 and a fifty-two week high of $89.98. The business's fifty day moving average is $73.43 and its two-hundred day moving average is $69.35. The firm has a market cap of $307.05 million, a P/E ratio of 21.15 and a beta of 1.15.

Read Our Latest Research Report on NVEC

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

NASDAQ:NNDM traded down $0.04 during mid-day trading on Friday, hitting $1.49. The company had a trading volume of 2,995,496 shares, compared to its average volume of 2,496,971. Nano Dimension has a fifty-two week low of $1.34 and a fifty-two week high of $2.74. The business's fifty day moving average is $1.53 and its two-hundred day moving average is $1.82. The firm has a market cap of $322.66 million, a P/E ratio of -3.71 and a beta of 1.13.

Read Our Latest Research Report on NNDM

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of Clene stock traded down $0.01 during trading hours on Friday, hitting $3.65. The company's stock had a trading volume of 115,372 shares, compared to its average volume of 46,506. Clene has a 12 month low of $2.28 and a 12 month high of $6.96. The stock has a 50 day moving average of $3.72 and a 200 day moving average of $3.81. The company has a market capitalization of $30.19 million, a PE ratio of -0.90 and a beta of 0.55.

Read Our Latest Research Report on CLNN

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ:BDRX traded down $0.01 during mid-day trading on Friday, reaching $0.88. 127,809 shares of the stock were exchanged, compared to its average volume of 1,320,313. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.01. Biodexa Pharmaceuticals has a one year low of $0.78 and a one year high of $19.50. The stock's 50 day simple moving average is $1.00 and its 200-day simple moving average is $2.11.

Read Our Latest Research Report on BDRX

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of NASDAQ:CLNNW remained flat at $0.03 during mid-day trading on Friday. The company had a trading volume of 18,687 shares, compared to its average volume of 11,007. Clene has a fifty-two week low of $0.02 and a fifty-two week high of $0.08. The business's 50 day moving average price is $0.03 and its 200 day moving average price is $0.03.

Read Our Latest Research Report on CLNNW

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.